Neurofilament light chain (NfL) is an established therapy response biomarker in ALS as superoxide dismutase1 (SOD1)‐ALS patients treated with the antisense oligonucleotide tofersen show a decrease in NfL. The gene discussed is NEFL; the disease is amyotrophic lateral sclerosis.